Premium
A Tumor‐Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers
Author(s) -
Ye Mingzhou,
Han Yuxin,
Tang Jianbin,
Piao Ying,
Liu Xiangrui,
Zhou Zhuxian,
Gao Jianqing,
Rao Jianghong,
Shen Youqing
Publication year - 2017
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201702342
Subject(s) - prodrug , multiple drug resistance , doxorubicin , reactive oxygen species , nad+ kinase , materials science , nanoparticle , drug resistance , cancer cell , pharmacology , cancer research , combinatorial chemistry , cancer , nanotechnology , chemotherapy , biology , chemistry , biochemistry , enzyme , microbiology and biotechnology , genetics
A cascade amplification release nanoparticle (CARN) is constructed by the coencapsulation of β‐lapachone and a reactive‐oxygen‐species (ROS)‐responsive doxorubicin (DOX) prodrug, BDOX, in polymeric nanoparticles. Releasing β‐lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase‐1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.